ArticleFrontiers in immunology2025

Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis.

Yanan Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.